Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseMyelofibrosis, PrimaryMyelofibrosis, SecondarySubgroupICD10D47.4MeSHPrimary MyelofibrosisSequenceChemotherapyChemo-substanceFedratinibChemo-substanceFedratinibChemo-substanceFedratinibChemo-substanceFedratinibNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronSupportive substanceDexamethasoneGranisetronNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (ASCO)HeadacheHepatotoxicityNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorTalpaz MDiseasehigh-risk primäre Myelofibrose, Post-Polycythaemia Vera-Myelofibrose oder Post-Essentielle Thrombozythämie-MyelofibroseOriginUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, USAProtocols in Revision 1 protocol foundProtocols under revision.Fedratinib 400, Primary Myelofibrosis (PID1740 V1.1)
